GlassScriptPhysician profile
Mary Guell
NPI 1619157591
$4,908.13
in general payments reported to CMS, 2019-2025
21 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $567 · 2023: $1,498 · 2024: $1,625 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,150 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,149.69 |
| Education | $191.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $887.49 | 2021-2025 | Krystexxa, Tavneos, Aranesp |
| Travere Therapeutics, INC. | $824.39 | 2023-2025 | Filspari |
| Astrazeneca Pharmaceuticals LP | $542.39 | 2021-2025 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $505.83 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $370.54 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $364.00 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Mallinckrodt Hospital Products INC. | $280.45 | 2023-2025 | Acthar |
| Opko Pharmaceuticals, LLC | $224.30 | 2021-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $206.46 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $172.07 | 2021-2025 | Jynarque |
| Vantive US Healthcare LLC | $121.03 | 2025 | Renal - Pd |
| Calliditas Therapeutics US INC. | $84.40 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $73.21 | 2024 | Benlysta |
| Ardelyx, INC. | $68.84 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $44.85 | 2023-2024 | Accrufer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $31.76 | 2021 | |
| Genzyme Corporation | $28.64 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $23.88 | 2023 | |
| Ani Pharmaceuticals, INC. | $19.68 | 2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $17.96 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $15.96 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Guell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.